Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A More COMPLETE Picture of Revascularization in STEMI

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Partial Oral Therapy for Osteomyelitis and Endocarditis. Reply

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effects of Serelaxin in Patients with Acute Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Matthew R Smith
  • Fred Saad
  • Simon Chowdhury
  • Stéphane Oudard
  • Boris A Hadaschik
  • Julie N Graff
  • David Olmos
  • Paul N Mainwaring
  • Ji Youl Lee
  • Hiroji Uemura
  • Angela Lopez-Gitlitz
  • Géralyn C Trudel
  • Byron M Espina
  • Youyi Shu
  • Youn C Park
  • Wayne R Rackoff
  • Margaret K Yu
  • Eric J Small
  • SPARTAN Investigators
  • Klaus Brasso (Medlem af forfattergruppering)
Vis graf over relationer

BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis.

METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. All the patients continued to receive androgen-deprivation therapy. The primary end point was metastasis-free survival, which was defined as the time from randomization to the first detection of distant metastasis on imaging or death.

RESULTS: A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo group). In the planned primary analysis, which was performed after 378 events had occurred, median metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%).

CONCLUSIONS: Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204 .).

OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Vol/bind378
Udgave nummer15
Sider (fra-til)1408-1418
Antal sider11
ISSN0028-4793
DOI
StatusUdgivet - 12 apr. 2018

ID: 53667802